semaglutide cardiovascular outcomes study news SELECT Trial Oral Semaglutide and Cardiovascular Outcomes

Next, we demonstrated ferroptosis-induced accumulation of cellular lipid hydroperoxides following RSL3 treatment

Iucci emphasizes that the risk is not limited to GLP 1 medications alone

14 However, concerns remain about potential side effects, including an increased risk of thyroid cancer

Highlights: Up to 28.7% weight loss in a 68-week late-stage trial Reduced knee osteoarthritis pain by up to 62.6% First triple-hormone injection targeting GLP-1, GIP, and glucagon Trusted Source Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial Go to source)

Weight Loss Medication Tracker Phaze supports 14 GLP-1 medication options including Ozempic, Mounjaro, Wegovy, Wegovy Pill, Zepbound, Rybelsus, Retatrutide, Survodutide, Orforglipron, Pemvidutide, Bioglutida, and CagriSema

doi: 10.1161/ATVBAHA.111.229765